Hypoxia-inducible factor-1 drives annexin A2 system-mediated perivascular fibrin clearance in oxygen-induced retinopathy in mice

Blood

Volumn 118, Issue 10, 2011, Pages 2918-2929

  Huang, Bihui ^a,b   Deora, Arun B ^a   He, Kai Li ^a,f   Chen, Kang ^c   Sui, Guangzhi ^a,g   Jacovina, Andrew T ^a   Almeida, Dena ^a   Hong, Peng ^d   Burgman, Paul ^e   Hajjar, Katherine A ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; HYPOXIA INDUCIBLE FACTOR 1; LIPOCORTIN 2; OXYGEN; PLASMIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; ENDOTHELIUM CELL; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; RETINA NEOVASCULARIZATION; RETINOPATHY; TRANSCRIPTION INITIATION;

EID: 80052684642     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-341214     Document Type: Article

References (54)

1. Chen J, Smith LEH. Retinopathy of prematurity. Angiogenesis. 2007;10(2):133-140. (Pubitemid 46440629)
2. Sapieha P, Joyal JS, Rivera JC, et al. Retinopathy of prematurity: Understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest. 2010;120(9):3022-3032.
3. Gerke V, Creutz CE, Moss SE. Annexins: Linking Ca++ signalling to membrane dynamics. Nat Rev Mol Cell Biol. 2005;6(6):449-461. (Pubitemid 40780557)
4. Dassah M, Deora A, He K, Hajjar KA. The endothelial cell annexin A2 system and vascular fibrinolysis. Gen Physiol Biophys. 2009;28:F20-F28.
5. Kwon M, MacLeod TJ, Zhang Y, Waisman DM. S100A10, annexin A2, and annexin A2 heterotetramer as candidate plasmnogen receptors. Front Biosci. 2005;10:300-325. (Pubitemid 40543035)
6. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator: I. Identity with annexin II. J Biol Chem. 1994;269(33):21191-21197.
7. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator. II: annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem. 1994;269(33):21198-21203.
8. O'Connell PA, SuretteAP, Liwski RS, Svenningsson P, Waisman DM. S100A10 regulates plasminogen-dependent macrophage invasion. Blood. 2010;116(7):1136- 1146.
9. He K, Deora AB, Xiong H, et al. Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner, S100A10/p11. J Biol Chem. 2008;283(28):19192-19200.
10. Ling Q, Jacovina AT, Deora AB, et al. Annexin II is a key regulator of fibrin homeostasis and neoangiogenesis. J Clin Invest. 2004;113(1):38-48. (Pubitemid 38541630)
11. Jacovina AT, Deora AB, Ling Q, et al. Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2-dependent fibrinolysis. J Clin Invest. 2009;119(11):3384-3394.
12. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35(1):101-111. (Pubitemid 24046832)
13. Chen J, Connor KM, Aderman CM, Smith LEH. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008;118(2):526-533. (Pubitemid 351206543)
14. Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: A model of vessel loss, vessel regrowth and pathological abgiogenesis Nat Protocols. 2009;4(11):1565-1573.
15. Deora AB, Kreitzer G, Jacovina AT, Hajjar KA. An annexin 2 phosphorylation switch mediates its p11-dependent translocation to the cell surface. J Biol Chem. 2004;279(42):43411-43418. (Pubitemid 39390640)
16. Fukuda R, Zhang H, Kim J, Shimoda L, Dang CV, Semenza GL. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell. 2007;129(1):111-122. (Pubitemid 46507584)
17. He T, Zhou S, Da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998;95(5):2509-2514. (Pubitemid 28145972)
18. Cesarman-Maus G, Rios-Luna NP, Deora AB, et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood. 2006;107(11):4375-4382. (Pubitemid 43801363)
19. Kren BT, Steer CJ. Posttranscriptional regulation of gene expression in liver regeneration: role of mRNA stability. FASEB J. 1996;10(5):559-573. (Pubitemid 26141168)
20. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604-4613. (Pubitemid 26272112)
21. Chachami G, Simos G, Hatziefthimiou A, Bonanou S, Molyvdas P, Paraskeva E. Cobalt induces hypoxia-inducible factor-1alpha expression in airway smooth muscle cells by a reactive oxygen species- and PI3K-dependent mechanism. Am J Respir Cell Mol Biol. 2004;31(5):544-551. (Pubitemid 39463403)
22. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is a key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 2003;22(6):4082-4090. (Pubitemid 37021737)
23. Pizzo SV, Schwartz ML, Hill RL, McKee PA. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin. J Clin Invest. 1972;51(11):2841-2859.
24. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57(6):1005-1032. (Pubitemid 29313210)
25. Rey S, Semenza GL. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodeling. Cardiovasc Res. 2010;86(2):236-242.
26. Manalo DJ, Rowan A, Lavoie T, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005;105(2):659-669. (Pubitemid 40070750)
27. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92(12):5510-5514.
28. Maxwell PH, Wiesener MS, Chang GW, et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271-275. (Pubitemid 29246458)
29. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-1alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468-472. (Pubitemid 32335942)
30. Ozaki H, Yu AY, Della N, et al. Hypoxia inducible factor-1alpha is increased in ischemic retina: Temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci. 1999;40(1):182-189. (Pubitemid 29029587)
31. Mowat FM, Luhmann UFO, Smith AJ, et al. HIF-1alpha and HIF-2alpha are differentially activated in distinct cell populations in retinal ischaemia. PLoS One. 2010;5(6):e11103-e11112.
32. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugger JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995;375(6532):577-581.
33. Loskutoff DJ, Quigley JP. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest. 2000;106(12):1441-1443. (Pubitemid 32038581)
34. Falcone DJ, McCaffrey TA, Haimovitz-Friedman A, Vergilio JA, Nicholson AC. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation. J Biol Chem. 1993;268(16):11951-11958. (Pubitemid 23168155)
35. Buluk K, Malofiegen M. The pharmacologic properties of fibrinogen degradation products. Br J Pharmacol. 1969;35(1):79-89.
36. Richardson DL, Pepper DS, Kay AB. Chemotaxis for human monocytes by fibrinogen degradation products. Br J Haematol. 1976;32(4):507-513.
37. Bootle-Wilbraham CA, Tazzyman S, Thompson WD, Stirk CM, Lewis CE. Fibrin fragment E stimulates the proliferation, migration, and differentiation of human microvascular endothelial cells in vitro. Angiogenesis. 2001;4(4):269-275. (Pubitemid 34832372)
38. Guo YH, Hernandez I, Isermann B, et al. Caveolin-1-dependent apoptosis induced by fibrin degradation products. Blood. 2009;113(18):4431-4439.
39. Naito M, Stirk CM, Smith EB, Thompson WD. Smooth muscle cell outgrowth stimulated by fibrin degradation products. Thromb Res. 2000;98(2):165-174.
40. Stahl A, Connor KM, Sapieha P, et al. The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci. 2010;51(6):2813-2826.
41. Hardy P, Beauchamp M, Sennlaub F, et al. New insights into the retinal circulation: Inflammatory lipid mediators in ischemic retinopathy. Prostaglandins Leukot Essent Fatty Acids. 2005;72(5):301-325. (Pubitemid 40590052)
42. Zhang SX, Ma JX, Sima J, et al. Genetic differences in susceptibility to the blood-retina barrier breakdown in diabetes and oxygen-induced retinopathy. Am J Pathol. 2005;166(1):313-321. (Pubitemid 40051683)
43. Fletcher EL, Downie LE, Hatzopoulos K, et al. The significance of neuronal and glial cell changes in the rat retina during oxygen-induced retinopathy. Doc Ophthalmol. 2010;120(1):67-86.
44. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-615.
45. Multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol. 1990;108(10):1408-1416.
46. Good WV. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-250. (Pubitemid 40706105)
47. Mantagos IS, Vanderveen DK, Smith LEH. Emerging treatments for retinopathy of prematurity. Sem Ophthalmol. 2009;24(2):82-86.
48. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol. 2009;148:536-543.
49. Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: A retrospective analysis. Critical Care. 2010;14(4):R148-R162.
50. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354(4):353-365. (Pubitemid 43145060)
51. Hocker JR, Saving KL. Fatal aortic thrombosis in a neonate during infusion of epsilon-aminocaproic acid. J Ped Surgery. 1995;30(10):1490-1492.
52. Albisetti M. The fibrinolytic system in children. Sem Thromb Haemost. 2009;29:339-347.
53. Kingsmore SF, Kennedy N, Halliday HL, et al. Identification of diagnostic biomarkers for infection in premature infants. Mol Cell Proteomics. 2008;7(10):1863-1875.
54. Lima e Silva R, Shen J, Gong YY, et al. Agents that bind annexin A2 suppress ocular neovascularization. J Cell Physiol. 2010;225(3):855-864.